Naldemedine
From Wikipedia, the free encyclopedia
 | |
|---|---|
| Systematic (IUPAC) name | |
| 17-(cyclopropylmethyl)-6,7-didehydro-4,5α-epoxy-3,6,14-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]morphinan-7-carboxamide | |
| Clinical data | |
| Legal status | Investigational New Drug |
| Routes | Oral |
| Identifiers | |
| CAS number | 916072-89-4 1345728-04-2 (tosylate) |
| ATC code | None |
| PubChem | CID 135626906 |
| Chemical data | |
| Formula | C32H34N4O6 |
| Mol. mass | 570.63556 g/mol |
| SMILES
| |
Naldemedine (INN, USAN; S-297,995) is a peripherally-selective μ-opioid receptor antagonist under development by Shionogi for the treatment of opioid-induced adverse effects including constipation, nausea, and vomiting.[1][2][3] Clinical studies have thus far found it to possess statistically significant effectiveness for these indications and to be generally well-tolerated with predominantly mild to moderate gastrointestinal side effects.<ref name="Sprawls1997" /[2] No effects indicative of central opioid withdrawal or impact on the analgesic or mydriatic effects of co-administered opioids have been observed.[1] As of May 2012, naldemedine is in phase IIb clinical trials in the United States and Japan.[4]
See also
References
- ↑ 1.0 1.1 De Sarro, Giovambattista; Kelly S. Sprawls, Egilius L.H. Spierings, Dustin Tran (2012-03-07). "Drugs in Development for Opioid-Induced Constipation". In Catto-Smith G., Anthony. Constipation - Causes, Diagnosis and Treatment. p. 7. doi:10.5772/30377. ISBN 978-953-51-0237-3. Retrieved 12 May 2012.
- ↑ 2.0 2.1 Shionogi (2009-03-27). "Research and Development at Shionogi (as of March 2009)" (PDF). Retrieved 2012-05-12.
- ↑ Nagase H, Fujii H (2011). "Opioids in preclinical and clinical trials". Topics in Current Chemistry 299: 29–62. PMID 21630515.
- ↑ Shionogi (May 2012). "Pipeline (as of May 2012)" (PDF). Retrieved 2012-05-12.
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.